Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

Archive, CME credit no longer available
Release Date: October 1, 2010
Expiration Date: October 2, 2011

The 13th Annual Clinical Conference for the Ryan White HIV/AIDS Program Parts A, B, C, and D practitioners was held in conjunction with the 2010 Ryan White HIV/AIDS Program Grantee Meeting, “Twenty Years of Leadership, A Legacy of Care,” from August 23-25, 2010, at the Marriott Wardman Park Hotel in Washington, DC.

The goal of the Clinical Conference was to provide a comprehensive overview of current clinical issues in HIV management and current strategies in HIV medical care for practitioners in Ryan White Parts A, B, C, and D funded programs. You may view and download a copy of the Clinical Conference syllabus and key slides at http://www.iasusa.org/rwprogram2010.

The Clinical Conference was supported by and planned in collaboration with staff from the HIV/AIDS Bureau (HAB), Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services, and Southeast AIDS Training and Education Center (SEATEC). This CME program is sponsored by the IAS–USA under the HRSA contract number HHSH250200900010c.

The Webcast activity consists of audio and visual recording of 18 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.

To view a particular presentation, the learner should click on the presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he or she chooses. The learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of the Clinical Conference, participants will be able to do the following:

• Design antiretroviral strategies that consider new data on:
  • Initial therapy
  • Interpretation of resistance test results
  • Antiretroviral regimen failure
  • Drug-drug interactions
• Explain the key clinical aspects of neurocognitive and cardiovascular complications in HIV disease
• Describe current data on new investigational drugs for hepatitis C virus as they impact the potential for future treatment
• Design appropriate interventions for HIV patients with mental health issues
• Explain the successful models for HIV testing and linkage to medical care
• Describe the incidence and management of oral and dermatologic manifestations of HIV disease
• Identify current treatment challenges in HIV care as they relate to the aging population and the transgender population
• Describe current data on post-exposure prophylaxis
• Develop practical plans for improving patient retention in care
• Identify and differentiate new diagnostics for sexually transmitted diseases
  

CME Credit

CME Accreditation Statement
This Clinical Conference Webcast is sponsored by the International AIDS Society–USA. The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The International AIDS Society–USA designates this educational activity for a maximum of 11.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Intended Audience for CME Credit

This online CME activity is designed for physicians, physician assistants, nurse practitioners, and other direct clinical care providers who are actively involved in HIV patient care in Ryan White funded programs. Specifically, these activities have been designed for physicians who:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV/AIDS
• Are currently active in HIV/AIDS research

Course Faculty

Co-Chairs

Laura W. Cheever, MD, ScM
Deputy Associate Administrator
Chief Medical Officer, HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland

Ronald H. Goldschmidt, MD
Professor of Clinical Family and Community Medicine
Vice Chair, UCSF Department of Family and Community Medicine
Director, National HIV/AIDS Clinicians'
Consultation Center
University of California San Francisco
San Francisco, CA

Michael S. Saag, MD
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Faculty

Andrew F. Angelino, MD
Associate Professor
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Laura W. Cheever, MD, ScM
Deputy Associate Administrator
Chief Medical Officer, HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland

Carlos del Rio, MD
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine
Emory University School of Medicine
Hubert Professor and Chair
Department of Global health
Atlanta, Georgia

Madeline B. Deutsch, MD
Lead Physician
Transgender Health Program
Los Angeles Gay & Lesbian Center
Physician, Private Practice
San Francisco, California

Betty J. Dong, PharmD
Professor of Clinical Pharmacy
University of California San Francisco
School of Pharmacy
National HIV/AIDS Clinicians’ Consultation Center
San Francisco, California

Emily Erbelding, MD, MPH
Deputy Director, Division of AIDS
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, Maryland

Thomas P. Giordano, MD, MPH
Assistant Professor of Medicine
Baylor College of Medicine
Scientist, Health Services Research and Development Center of Excellence
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas

Ronald H. Goldschmidt, MD
Professor of Clinical Family and Community Medicine
Vice Chair, UCSF Department of Family
and Community Medicine
Director, National HIV/AIDS Clinicians'
Consultation Center
University of California San Francisco
San Francisco, CA

Carl Grunfeld, MD, PhD
Professor of Medicine
University of California San Francisco
Chief, Metabolism and Endocrine Sections
Veterans Affairs Medical Center
San Francisco, California

Nnemdi Kamanu Elias, MD, MPH
Acting Senior Deputy Director
HIV/AIDS, Hepatitis, STD and TB Administration (HAHSTA)
District of Columbia Department of Health
Washington, DC

Jeanne Marrazzo, MD, MPH
Professor of Medicine
University of Washington
Medical Director
Seattle STD/HIV Prevention Training Center
Seattle, Washington

Toby A. Maurer, MD
Professor
University of California San Francisco
San Francisco, California

Justin C. McArthur, MBBS, MPH
Professor of Neurology, Pathology, and Epidemiology
Director, Neurology Department
The John Hopkins University School of Medicine
Baltimore, Maryland

Susanna Naggie, MD
Assistant Professor of Medicine
Duke University School of Medicine
Durham Veterans Affairs Medical Center
Durham, North Carolina

Michael S. Saag, MD
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Robert W. Shafer, MD
Associate Professor of Medicine
Stanford University
Stanford, California

Jess Fogler Waldura, MD
Associate Clinical Professor
University of California San Francisco
Director, National Perinatal HIV Hotline
HIV/AIDS Physician Consultant
National HIV/AIDS Clinicians' Consultation Center
San Francisco, California

Jennifer Webster-Cyriaque, DDS, PhD
Associate Professor
University of North Carolina Chapel Hill
Chapel Hill, North Carolina



Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any real or apparent conflicts of interest of those parties are resolved prior to the education activity being delivered. Individuals who refuse to disclose financial interests may not participate in the CME activity.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on scientific advisory boards for GlaxoSmithKline, ViiV Healthcare, and Merck & Co, Inc, and has chaired a data and safety monitoring board for Achillion Pharmaceuticals, Inc. (Updated 08/09/10)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc, and Schering-Plough Corp. (Updated 08/11/10)

Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp, and Sanofi Pasteur. (Updated 08/10/10)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant to Abbott Laboratories. He has been a member of data and safety monitoring boards and endpoint adjudication committees for Gilead Sciences, Inc, and Sangamo Biosciences, Inc. He has been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, and ViiV Healthcare. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences, Inc, for research conducted by Dr Gallant. (Updated 08/10/10)

Roy M. Gulick, MD, MPH
Dr Gulick has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, MedImmune, LLC, ViiV Healthcare, and ViroStatics and as an investigator for research study grants (to Weill Cornell) from Pfizer Inc, Schering-Plough Corp, and Tibotec Therapeutics. (Updated 08/10/10)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 08/12/10)

Douglas D. Richman, MD
Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, Monogram Biosciences, Inc, Myriad Genetics, Inc, and Theraclone Sciences. He has been on an endpoint adjudication committee for Schering-Plough Corp and has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc, and a stock shareholder of Monogram Biosciences, Inc. (Updated 08/09/10)

Michael S. Saag, MD
Dr Saag has received grants and research support from and has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Monogram Biosciences, Inc, Pain Therapeutics, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Tibotec Therapeutics, and Tobira Therapeutics. (Updated 08/10/10)

Robert T. Schooley, MD
Dr Schooley has served as a consultant to Achillion Pharmaceuticals, Inc, Gilead Sciences, Inc, Inhibitex, Inc, Johnson & Johnson Services, Inc, Tobira Therapeutics, and Laboratory Corporation of America. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 08/10/10)

Paul A. Volberding, MD
Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc, and TaiMed Biologics, and on an endpoint adjudication committee for Schering-Plough Corp. He has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Pfizer Inc, and Tobira Therapeutics. (Updated 08/10/10)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Angelino has served as a consultant to Abbott Laboratories, BioMarin Pharmaceutical Inc, and Boehringer Ingelheim Pharmaceuticals, Inc. (Updated 08/10/10)

Dr Cheever has no relevant financial affiliations to disclose. (Updated 06/09/10)

Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp, and Sanofi Pasteur. (Updated 08/10/10)

Dr Deutsch has no relevant financial affiliations to disclose. (Updated 08/01/10)

Dr Dong has received grants and research support from Merck & Co, Inc (ended March 2010). (Updated 07/01/10)

Dr Erbelding has no relevant financial affiliations to disclose. (Updated 08/11/10)

Dr Giordano has no relevant financial affiliations to disclose. (Updated 07/26/10)

Dr Goldschmidt has no relevant financial affiliations to disclose. (Updated 08/10/10)

Dr Grunfeld has received grants and research
support from Theratechnologies, Inc. (Updated 08/10/10)

Dr Kamanu Elias has no relevant financial affiliations to disclose. (Updated 08/10/10)

Dr Marrazzo has served as a scientific advisor to AstraZeneca, Bayer Diagnostics, and Gilead Sciences, Inc. (Updated 08/10/10)

Dr Maurer has no relevant financial affiliations to disclose. (Updated 07/19/10)

Dr McArthur has no relevant financial affiliations to disclose. (Updated 07/20/10)

Dr Naggie has no relevant financial affiliations to disclose. (Updated 08/03/10)

Dr Saag has received grants and research support from and has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Monogram Biosciences, Inc, Pain Therapeutics, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Tibotec Therapeutics, and Tobira Therapeutics. (Updated 08/10/10)

Dr Shafer has received grants and research support from Gilead Sciences, Inc, Merck & Co, Inc, and Roche Laboratories. He has served as a consultant or as a scientific advisor to Bristol-Myers Squibb, Celera Corp, Schering-Plough Corp, and Siemens Medical Solutions USA, Inc. (Updated 07/30/10)

Dr Waldura has no relevant financial affiliations to disclose. (Updated 08/11/10)

Dr Webster-Cyriaque has no relevant financial affiliations to disclose. (Updated 08/11/10)


IAS–USA CME Staff

Ms Jacobsen has no relevant financial affiliations to disclose (see above).

Ms Balderas has no relevant financial affiliations to disclose. (Updated 08/12/10)

Program Development Committee

Dr Carmichael has no relevant financial affiliations to disclose. (Updated 08/10/10)

Ms Fullerton has no relevant financial affiliations to disclose. (Updated 08/10/10)

Ms Richardson has no relevant financial affiliations to disclose. (Updated 08/11/10)

Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services, the AIDS Education and Training Centers National Resource Center, and the International AIDS Society–USA.


Contact Information

If you have any questions about this Web-based CME activity, please contact the International AIDS Society–USA:

International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org

I have read these instructions and understand them.